|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin
A prospective randomized pharmacodynamic study
1 Profil Institut für Stoffwechselforschung, Neuss, Germany
2 Pfizer Global Research and Development, Pfizer, Groton, Connecticut
Address correspondence and reprint requests to Tim Heise, MD, Profil Institut für Stoffwechselforschung, Hellersbergstr 9, D-41460 Neuss, Germany. E-mail: tim.heise{at}profil-research.de
OBJECTIVE—To assess the impact of the development of high- or low-affinity insulin antibodies (IABs) on postprandial glucose tolerance, duration of insulin action, and clinical safety in patients with type 1 diabetes receiving inhaled insulin (Exubera).
RESEARCH DESIGN AND METHODS—This study consisted of a prospective, randomized, open-label, parallel-group trial in which 47 patients with type 1 diabetes received NPH insulin twice daily plus either premeal inhaled insulin (INH group; n = 24) or premeal subcutaneous regular insulin (SC group; n = 23) for 24 weeks. Meal challenge and euglycemic clamp studies were performed on consecutive days at baseline, week 12, and week 24. Adverse events were monitored.
RESULTS—For the INH and SC groups, mean (±SD) IAB levels were 3.5 ± 3.9 and 2.6 ± 4.1 µU/ml at baseline, respectively, compared with 101.4 ± 140.4 and 4.3 ± 9.4 µU/ml at week 24. At week 24, the changes from baseline were similar for the INH and SC groups for maximal plasma glucose concentration (Cmax) (adjusted ratio for treatment group difference 0.99 [90% CI 0.95–1.03]), area under the plasma glucose concentration time curve (adjusted ratio for treatment group difference 0.98 [0.88–1.08]), and duration of insulin action (adjusted treatment group difference 29 min [–49 to 108]). No adverse events were attributed to IABs.
CONCLUSIONS—In patients with type 1 diabetes treated with inhaled insulin, development of high- or low-affinity IABs did not impair postprandial glucose tolerance, alter the time-action profile of insulin, or impact tolerability. No clinical relevance of IABs was identified in this study.
Abbreviations: AUC, area under the curve • GIR, glucose infusion rate • IAB, insulin antibody
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. B. Drummond, P. F. Schwartz, W. T. Duggan, J. G. Teeter, R. J. Riese, R. C. Ahrens, R. O. Crapo, R. D. England, N. R. MacIntyre, R. L. Jensen, et al. Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease Am. J. Respir. Crit. Care Med., August 1, 2008; 178(3): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gifondorwa, M. B. Robinson, C. D. Hayes, A. R. Taylor, D. M. Prevette, R. W. Oppenheim, J. Caress, and C. E. Milligan Exogenous Delivery of Heat Shock Protein 70 Increases Lifespan in a Mouse Model of Amyotrophic Lateral Sclerosis J. Neurosci., November 28, 2007; 27(48): 13173 - 13180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Q. Pham, H. Cohen, and V. Chu Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Noronha Neutralizing antibodies to interferon Neurology, June 12, 2007; 68(24_suppl_4): S16 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Skyler, L. Jovanovic, S. Klioze, J. Reis, W. Duggan, and for the Inhaled Human Insulin Type 1 Diabetes Stud Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes Diabetes Care, March 1, 2007; 30(3): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh and A. Collier Inhaled insulins Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan Counterpoint: No Time to Inhale: Arguments Against Inhaled Insulin in 2007 Diabetes Care, February 1, 2007; 30(2): 442 - 443. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ceglia, J. Lau, and A. G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med, November 7, 2006; 145(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Teeter and R. J. Riese Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin Therapy Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellary and A. H Barnett Review: Inhaled insulin: overcoming barriers to insulin therapy? The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 103 - 108. [Abstract] [PDF]
|
|
|
|
|
|
E. Chantelau The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. Diabetes Care, February 1, 2006; 29(2): 477 - 477. [Full Text] [PDF]
|
|
|
|
|
|
T. Heise, S. Bott, C. Tusek, J.-A. Stephan, T. Kawabata, D. Finco-Kent, C. Liu, and A. Krasner The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: Response to Chantelau et al. Diabetes Care, February 1, 2006; 29(2): 477 - 478. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |